Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:3224Q87.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome (also known as Gorlin-Cervenka syndrome or Cervenka syndrome) is an extremely rare genetic condition characterized by the combination of sensorineural hearing loss, genital anomalies, and bony fusion (synostosis) of the metacarpal and metatarsal bones in the hands and feet. The syndrome affects multiple body systems, primarily the auditory system, the skeletal system, and the urogenital system. Key clinical features include congenital sensorineural deafness, which may range from moderate to severe, abnormalities of the genitalia (such as hypospadias or cryptorchidism in males), and radiographic evidence of fusion between the fourth and fifth metacarpal and/or metatarsal bones. Additional skeletal anomalies may also be present. The condition has been described in only a very small number of families in the medical literature, making it one of the rarest syndromic forms of hearing loss. Because of its extreme rarity, the natural history and full phenotypic spectrum of this syndrome remain incompletely characterized. There is currently no specific curative treatment for this condition. Management is supportive and multidisciplinary, involving audiological intervention (such as hearing aids or cochlear implants), surgical correction of genital anomalies when indicated, and orthopedic evaluation for skeletal manifestations. Genetic counseling is recommended for affected families.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal cerebellar vermis morphologyHP:0002334Abnormal nasal morphologyHP:0005105
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome.

View clinical trials →

No actively recruiting trials found for Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome community →

No specialists are currently listed for Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Deafness-genital anomalies-metacarpal and metatarsal synostosis syndromeForum →

No community posts yet. Be the first to share your experience with Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome.

Start the conversation →

Latest news about Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome

No recent news articles for Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome

What is Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome?

Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome (also known as Gorlin-Cervenka syndrome or Cervenka syndrome) is an extremely rare genetic condition characterized by the combination of sensorineural hearing loss, genital anomalies, and bony fusion (synostosis) of the metacarpal and metatarsal bones in the hands and feet. The syndrome affects multiple body systems, primarily the auditory system, the skeletal system, and the urogenital system. Key clinical features include congenital sensorineural deafness, which may range from moderate to severe, abnormalities of the ge

How is Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome inherited?

Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome typically begin?

Typical onset of Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome is neonatal. Age of onset can vary across affected individuals.